106 related articles for article (PubMed ID: 23984899)
1. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.
Honoki K; Tsujiuchi T
Expert Rev Anticancer Ther; 2013 Aug; 13(8):983-96. PubMed ID: 23984899
[TBL] [Abstract][Full Text] [Related]
2. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development.
Rubio R; Gutierrez-Aranda I; Sáez-Castillo AI; Labarga A; Rosu-Myles M; Gonzalez-Garcia S; Toribio ML; Menendez P; Rodriguez R
Oncogene; 2013 Oct; 32(41):4970-80. PubMed ID: 23222711
[TBL] [Abstract][Full Text] [Related]
3. Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy.
Burns JS; Safwat A; Grisendi G; Kassem M; Dominici M
Cancer Lett; 2012 Dec; 325(1):1-10. PubMed ID: 22659735
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells: From stem cells to sarcomas.
Lye KL; Nordin N; Vidyadaran S; Thilakavathy K
Cell Biol Int; 2016 Jun; 40(6):610-8. PubMed ID: 26992453
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of p21(Cip1/Waf1) enhances proliferation, the expression of stemness markers, and osteogenic potential in human mesenchymal stem cells.
Yew TL; Chiu FY; Tsai CC; Chen HL; Lee WP; Chen YJ; Chang MC; Hung SC
Aging Cell; 2011 Apr; 10(2):349-61. PubMed ID: 21342417
[TBL] [Abstract][Full Text] [Related]
6. Primary cardiac sarcomas may develop from resident or bone marrow-derived mesenchymal stem cells: use of immunohistochemistry including CD44 and octamer binding protein 3/4.
Hegyi L; Thway K; Fisher C; Sheppard MN
Histopathology; 2012 Nov; 61(5):966-73. PubMed ID: 22804494
[TBL] [Abstract][Full Text] [Related]
7. In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Xu S; De Becker A; De Raeve H; Van Camp B; Vanderkerken K; Van Riet I
Biochem Biophys Res Commun; 2012 Aug; 424(3):391-7. PubMed ID: 22771324
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the biological characteristics of mesenchymal stem cells from bone marrow and peripheral blood of rats.
Fu WL; Zhang JY; Fu X; Duan XN; Leung KK; Jia ZQ; Wang WP; Zhou CY; Yu JK
Tissue Eng Part A; 2012 Sep; 18(17-18):1793-803. PubMed ID: 22721583
[TBL] [Abstract][Full Text] [Related]
9. Oxygen effects on senescence in chondrocytes and mesenchymal stem cells: consequences for tissue engineering.
Moussavi-Harami F; Duwayri Y; Martin JA; Moussavi-Harami F; Buckwalter JA
Iowa Orthop J; 2004; 24():15-20. PubMed ID: 15296200
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells, cancer challenges and new directions.
Serakinci N; Fahrioglu U; Christensen R
Eur J Cancer; 2014 May; 50(8):1522-30. PubMed ID: 24613620
[TBL] [Abstract][Full Text] [Related]
11. Concise review: mesenchymal tumors: when stem cells go mad.
Mohseny AB; Hogendoorn PC
Stem Cells; 2011 Mar; 29(3):397-403. PubMed ID: 21425403
[TBL] [Abstract][Full Text] [Related]
12. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo.
Rubio R; García-Castro J; Gutiérrez-Aranda I; Paramio J; Santos M; Catalina P; Leone PE; Menendez P; Rodríguez R
Cancer Res; 2010 May; 70(10):4185-94. PubMed ID: 20442289
[TBL] [Abstract][Full Text] [Related]
13. Methods for assessing effects of Wnt/β-catenin signaling in senescence of mesenchymal stem cells.
Wang HJ; Tan YZ
Methods Mol Biol; 2013; 976():111-30. PubMed ID: 23400438
[TBL] [Abstract][Full Text] [Related]
14. Do stem-like cells play a role in drug resistance of sarcomas?
Honoki K
Expert Rev Anticancer Ther; 2010 Feb; 10(2):261-70. PubMed ID: 20132001
[TBL] [Abstract][Full Text] [Related]
15. Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy.
Leal JA; Feliciano A; Lleonart ME
Med Res Rev; 2013 Jan; 33(1):112-38. PubMed ID: 21793013
[TBL] [Abstract][Full Text] [Related]
16. Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6.
Lin JT; Wang JY; Chen MK; Chen HC; Chang TH; Su BW; Chang PJ
Exp Cell Res; 2013 Aug; 319(14):2216-29. PubMed ID: 23751564
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming of mesenchymal stem cells by oncogenes.
Eid JE; Garcia CB
Semin Cancer Biol; 2015 Jun; 32():18-31. PubMed ID: 24938913
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Borghese C; Cattaruzza L; Pivetta E; Normanno N; De Luca A; Mazzucato M; Celegato M; Colombatti A; Aldinucci D
J Cell Biochem; 2013 May; 114(5):1135-44. PubMed ID: 23192362
[TBL] [Abstract][Full Text] [Related]
19. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.
Bernardo ME; Zaffaroni N; Novara F; Cometa AM; Avanzini MA; Moretta A; Montagna D; Maccario R; Villa R; Daidone MG; Zuffardi O; Locatelli F
Cancer Res; 2007 Oct; 67(19):9142-9. PubMed ID: 17909019
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations.
Wang J; Liao L; Wang S; Tan J
Cytotherapy; 2013 Aug; 15(8):893-904. PubMed ID: 23751203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
